More on IDYA

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (+100.0% Growth)
- Ratings (9.2 Score)

Upcoming Events

- Earnings (8/5/26 *Est.)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

IDEAYA Biosciences (NQ:IDYA)
Delayed: 33.19 +0.16 (0.48%)
Prev. Close $33.03  
Open$32.32 
52 Wk High$ 
52 Wk Low$ 
Day High$33.27 
Day Low$31.90 
P/E N/A  
EPS$ 
Volume727,690 

Friends, Peers and Foes (?): CATX, EXAS, ILMN, IR, LIFE (more...)

Mar 6, 2026 06:50 AM IDEAYA Biosciences (IDYA) Added to Citi Catalyst Watch List
Mar 2, 2026 07:18 PM Form 4 IDEAYA Biosciences, Inc. For: Mar 02 Filed by: Stein Jeffrey
Feb 27, 2026 07:00 PM IDEAYA doses first patient in Biocytogen's IDE034 cancer drug trial
Feb 27, 2026 07:00 PM Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA’s First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE034
Feb 27, 2026 06:00 AM IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Feb 25, 2026 06:00 AM IDEAYA Biosciences begins phase 1 trial of IDE034 cancer drug
Feb 25, 2026 06:00 AM IDEAYA begins phase 1 trial of cancer drug IDE034
Feb 25, 2026 06:00 AM IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE034, a Potential First-In-Class B7H3/PTK7 Bispecific TOP1 ADC
Feb 23, 2026 06:00 AM IDEAYA Biosciences appoints Dr. Theodora Ross as Chief Development Officer
Feb 23, 2026 06:00 AM IDEAYA Biosciences Announces Appointment of Dr. Theodora (Theo) Ross, M.D., Ph.D., as Chief Development Officer
View All Articles

Entities mentioned with IDYA

View All Entities